Burke PJ - Search Results

1

A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia.

Gore SD, Rowinsky EK, Miller CB, Griffin C, Chen TL, Borowitz M, Donehower RC, Burks KL, Armstrong DK, Burke PJ, Grever MR, Kaufmann SH. Gore SD, et al. Among authors: burke pj. Clin Cancer Res. 1998 Nov;4(11):2677-89. Clin Cancer Res. 1998. PMID: 9829730 Clinical Trial.

2

Phase I and pharmacodynamic study of taxol in refractory acute leukemias.

Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, Donehower RC. Rowinsky EK, et al. Among authors: burke pj. Cancer Res. 1989 Aug 15;49(16):4640-7. Cancer Res. 1989. PMID: 2568175

3

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng YC, Grochow LB, Kaufmann SH. Rowinsky EK, et al. Among authors: burke pj. J Clin Oncol. 1994 Oct;12(10):2193-203. doi: 10.1200/JCO.1994.12.10.2193. J Clin Oncol. 1994. PMID: 7931489 Clinical Trial.

4

Addition of etoposide to initial therapy of adult acute lymphoblastic leukemia: a combined clinical and laboratory study.

Kaufmann SH, Karp JE, Burke PJ, Gore SD. Kaufmann SH, et al. Among authors: burke pj. Leuk Lymphoma. 1996 Sep;23(1-2):71-83. doi: 10.3109/10428199609054804. Leuk Lymphoma. 1996. PMID: 9021688 Clinical Trial.

5

Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.

Gore SD, Weng LJ, Jones RJ, Cowan K, Zilcha M, Piantadosi S, Burke PJ. Gore SD, et al. Among authors: burke pj. Clin Cancer Res. 1995 Mar;1(3):295-303. Clin Cancer Res. 1995. PMID: 9815985 Clinical Trial.

6

Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy.

Sotomayor EM, Piantadosi S, Miller CB, Karp JE, Jones RJ, Rowley SD, Kaufmann SH, Braine H, Burke PJ, Gore SD. Sotomayor EM, et al. Among authors: burke pj. Leuk Res. 2002 May;26(5):461-71. doi: 10.1016/s0145-2126(01)00175-8. Leuk Res. 2002. PMID: 11916520

7

Changes in topoisomerase I levels and localization during myeloid maturation in vitro and in vivo.

Kaufmann SH, Charron M, Burke PJ, Karp JE. Kaufmann SH, et al. Among authors: burke pj. Cancer Res. 1995 Mar 15;55(6):1255-60. Cancer Res. 1995. PMID: 7882318

8

Effects of rhGM-CSF on intracellular ara-C pharmacology in vitro in acute myelocytic leukemia: comparability with drug-induced humoral stimulatory activity.

Karp JE, Burke PJ, Donehower RC. Karp JE, et al. Among authors: burke pj. Leukemia. 1990 Aug;4(8):553-6. Leukemia. 1990. PMID: 2201833

9

Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors.

Rowinsky EK, Donehower RC, Spivak JL, Burke PJ, Griffin CA, Jones RJ. Rowinsky EK, et al. Among authors: burke pj. J Natl Cancer Inst. 1990 Dec 19;82(24):1926-31. doi: 10.1093/jnci/82.24.1926. J Natl Cancer Inst. 1990. PMID: 2250314

10

In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia.

Karp JE, Donehower RC, Enterline JP, Dole GB, Fox MG, Burke PJ. Karp JE, et al. Among authors: burke pj. Blood. 1989 Jan;73(1):24-30. Blood. 1989. PMID: 2910362 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

260 results

Search Page

Filters